Tremelimumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tremelimumab
Accession Number
DB11771
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Ticilimumab
External IDs
CP-675206
Categories
UNII
QEN1X95CIX
CAS number
745013-59-6

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Tremelimumab.
AbituzumabThe risk or severity of adverse effects can be increased when Tremelimumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Tremelimumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Tremelimumab.
AducanumabThe risk or severity of adverse effects can be increased when Tremelimumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Tremelimumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tremelimumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Tremelimumab.
AmatuximabThe risk or severity of adverse effects can be increased when Tremelimumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Tremelimumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911239
Wikipedia
Tremelimumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentCancer, Breast / Hormone Receptor Positive, HER2 Negative Breast Cancer1
0Active Not RecruitingTreatmentMalignant Neoplasms of Oropharynx1
1Active Not RecruitingOtherSolid Malignancies1
1Active Not RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Squamous Cell of Head and Neck / Esophagogastric Junction Neoplasms / Fallopian Tube Neoplasms / Neoplasms, Ovarian / Pancreatic Ductal Carcinoma / Small Cell Lung Carcinoma / Squamous Cell Carcinoma of Esophagus / Stomach Neoplasms / Triple Negative Breast Neoplasms1
1Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Biliary Tract Cancer / Cancer, Breast / Colorectal Cancers / Gastrooesophageal Cancer / Head and Neck Carcinoma / Lung Cancers / Melanoma1
1Active Not RecruitingTreatmentAdvanced Solid Tumors2
1Active Not RecruitingTreatmentCancer of the Ovary / Cancer, Breast / Cervical Cancers / Colorectal Cancers / Renal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentHepatocellular,Carcinoma / Liver Cancer / Liver Cell Caricinoma / Neoplasms, Hepatic1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1Active Not RecruitingTreatmentMetastatic Carcinoma in the Liver / MLH1 Gene Mutation / MSH6 Gene Mutation / PMS2 Gene Mutation / Stage IV Colorectal Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1Active Not RecruitingTreatmentMetastatic Anaplastic Thyroid Cancer1
1Active Not RecruitingTreatmentMetastatic Melanoma1
1Active Not RecruitingTreatmentRecurrent Melanoma / Stage IV Melanoma1
1Active Not RecruitingTreatmentSelected Advanced Solid Tumors1
1CompletedOtherPart A and B: Advanced Solid Malignancies / Part C: Malignant Mesothelioma1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMyelodysplastic Syndrome1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedTreatmentTumors, Solid1
1Not Yet RecruitingTreatmentColorectal Cancers1
1RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Melanoma / Metastatic1
1RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck / Lung Cancer Non-Small Cell Cancer (NSCLC) / Small Cell Lung Carcinoma1
1RecruitingTreatmentColorectal Cancers / Hepatic Metastases1
1RecruitingTreatmentDigestive Organs--Diseases / Larynx / LIP / Oral Cancers1
1RecruitingTreatmentHydronephrosis / Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant / Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant / Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant / Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant / Malignant Neoplasms of Urinary Tract / Renal Pelvis Urothelial Carcinoma / Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 / Stage II Renal Pelvis Cancer AJCC v7 / Stage II Ureter Cancer AJCC v7 / Stage II Urethral Cancer AJCC v7 / Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 / Stage III Renal Pelvis Cancer AJCC v7 / Stage III Ureter Cancer AJCC v7 / Stage III Urethral Cancer AJCC v7 / Stage IV Renal Pelvis Cancer AJCC v7 / Stage IV Ureter Cancer AJCC v7 / Stage IV Urethral Cancer AJCC v7 / Ureter Urothelial Carcinoma / Urethral Urothelial Carcinoma1
1RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Small Cell Lung Cancer Extensive Stage1
1RecruitingTreatmentMetastatic Endometrial cancer / Metastatic Vaginal Cancer / Metastatic Vulvar Cancer / Ovarian Cancer Metastatic / Recurrent Cervical Carcinoma / Recurrent Endometrial Cancer / Recurrent Gynecological Cancer / Recurrent Ovarian Carcinoma / Recurrent Vaginal Cancer / Recurrent Vulvar Cancer / Recurrent, IV-B Cervical cancer1
1RecruitingTreatmentProstatic Neoplasms1
1RecruitingTreatmentRelapsed/Refractory Solid Tumor Malignancies or Lymphoma1
1RecruitingTreatmentRenal Cancers / Renal Cell Adenocarcinoma1
1TerminatedTreatmentMelanoma1
1TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1TerminatedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentProstate Cancer1
1WithdrawnTreatmentBladder Cancers1
1WithdrawnTreatmentMalignant Neoplasm of Pancreas1
1, 2Active Not RecruitingTreatmentAdvanced Malignancy1
1, 2Active Not RecruitingTreatmentGastric or Gastroesophageal Junction Adenocarcinoma1
1, 2Active Not RecruitingTreatmentMalignant Melanoma1
1, 2CompletedTreatmentAdvanced Solid Tumors / Aggressive B-cell Lymphomas1
1, 2Not Yet RecruitingTreatmentHypopharynx Squamous Cell Carcinoma / Larynx Squamous Cell Carcinoma / Metastatic cutaneous squamous cell carcinoma / Metastatic Squamous Cell Carcinoma / Oral Cavity Squamous Cell Carcinoma / Oropharynx Squamous Cell Carcinoma / Paranasal Sinus Squamous Cell Carcinoma / Squamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2Not Yet RecruitingTreatmentTransitional Cell Carcinoma1
1, 2RecruitingTreatmentAbdominal wall neoplasm / Cancer of the Ovary / Fallopian Tube Cancer1
1, 2RecruitingTreatmentAdvanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck / Metastatic Squamous Cell Carcinoma of the Head and Neck1
1, 2RecruitingTreatmentBladder Cancers / Cancer, Breast / Cutaneous T-Cell Lymphoma (CTCL) / Head and Neck Squamous Cell Carcinoma (HNSCC) / Lymphoma, Cutaneous T-Cell / Melanoma / Neuroendocrine Carcinoma of the Skin / Prostate Cancer / Renal Cancers / Sarcomas / Testicular Cancer / Tumors, Solid1
1, 2RecruitingTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas / Neoplasms, Pancreatic1
1, 2RecruitingTreatmentCarcinoma, Colorectal / Colorectal Adenocarcinoma / Colorectal Cancers / Metastatic Disease / Microsatellite-Stable (MSS) Tumor / Neoplasms, Colorectal / Refractory Cancer1
1, 2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Renal Papillary Cell Carcinoma1
1, 2RecruitingTreatmentClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8 / Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 / Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 / Human Papillomavirus Positive / Oropharyngeal Squamous Cell Carcinoma / P16 Positive Neoplastic Cells Present / Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 / Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 / Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v81
1, 2RecruitingTreatmentEsophageal Cancers1
1, 2RecruitingTreatmentHead and Neck Carcinoma1
1, 2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Lung Cancers / Malignant Neoplasm of Esophagus1
1, 2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Metastatic cutaneous squamous cell carcinoma / Metastatic Squamous Cell Carcinoma1
1, 2RecruitingTreatmentInfiltrating Bladder Urothelial Carcinoma1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentMetastatic Colorectal Cancers1
1, 2RecruitingTreatmentMetastatic Gastric Cancers1
1, 2RecruitingTreatmentMetastatic Head and Neck Squamous Cell Carcinoma / Recurrent Head and Neck Squamous Cell Carcinoma1
1, 2RecruitingTreatmentNeoplasms1
1, 2RecruitingTreatmentOral Cavity Squamous Cell Carcinoma1
1, 2RecruitingTreatmentPrimary Peritoneal Carcinoma1
1, 2RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Lung Cancer / Stage IVA Lung Cancer / Stage IVB Lung Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas1
2Active Not RecruitingTreatmentAdvanced and/or Metastatic Sarcoma1
2Active Not RecruitingTreatmentCancer, Breast / Estrogen Receptor Positive Tumor / Hormone Antagonist / Menopause1
2Active Not RecruitingTreatmentCastration-Resistant Prostate Cancer (CRPC)1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentDurvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma / Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC1
2Active Not RecruitingTreatmentDysgerminoma / Germ Cell Tumors / Germinomatous Germ Cell Tumor / Nonseminomatous Germ Cell Tumor / Pineal Germ Cell Tumor / Seminoma1
2Active Not RecruitingTreatmentLung Cancer Metastatic1
2Active Not RecruitingTreatmentMalignant Gliomas / Recurrent Glioblastoma1
2Active Not RecruitingTreatmentMelanoma / Neoplasms / Neoplasms, Colorectal / Patients Who Have/Have Had Melanoma and Other Tumors / Prostatic Neoplasms / Renal Cell Adenocarcinoma1
2Active Not RecruitingTreatmentMicrosatellite Stable / Recurrent Colorectal Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Colorectal Cancer AJCC v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
2Active Not RecruitingTreatmentPancreatic Ductal Adenocarcinoma / Triple-Negative Breast Cancer (TNBC) / UBC (Urothelial Bladder Cancer)/ TNBC (Triple-negative Breast Cancer)/ PDAC (Pancreatic Ductal Adenocarcinoma) / Urothelial Bladder Cancer1
2Active Not RecruitingTreatmentRecurrent/Metastatic Squamous Cell Carcinoma of Head & Neck1
2Active Not RecruitingTreatmentUnresectable Pleural or Peritoneal Malignant Mesothelioma1
2CompletedOtherMelanoma1
2CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
2CompletedTreatmentNeoplasms, Colorectal1
2CompletedTreatmentRefractory Melanoma1
2CompletedTreatmentUveal Melanoma1
2Not Yet RecruitingTreatmentColorectal Cancers / Hepatic Metastases1
2Not Yet RecruitingTreatmentHypopharynx / Larynx / Oropharynx / Stage II-IVB Operable HNSCC Oral Cavity1
2Not Yet RecruitingTreatmentLocally Advanced Head and Neck Squamous Cell Carcinoma1
2Not Yet RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer / Squamous Non-Small Cell Lung Cancer1
2Not Yet RecruitingTreatmentRenal Cell Adenocarcinoma1
2Not Yet RecruitingTreatmentTumors, Solid1
2RecruitingOtherMesothelioma1
2RecruitingTreatmentAdenocarcinoma of the Bladder / Metastatic Bladder Cancer / Non-Transitional Cell Carcinoma of the Urothelial Tract / Small Cell of the Bladder / Squamous Cell Carcinoma of the Bladder1
2RecruitingTreatmentAdvanced Biliary Tract Carcinoma1
2RecruitingTreatmentAdvanced Rare Tumours1
2RecruitingTreatmentBRCA1 Gene Mutation / Brca2 Gene Mutation / Ovarian Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentBile Duct Carcinoma / Biliary Tract Neoplasms / Cholangiocarcinomas / Hapatocellular Carcinoma / Hepatocellular,Carcinoma / Liver Cancer / Liver Cell Caricinoma / Neoplasms, Hepatic1
2RecruitingTreatmentBiliary Tract Cancer / Hepatocellular,Carcinoma1
2RecruitingTreatmentBiliary Tract Neoplasms1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentBladder Urothelial Carcinoma / Stage IV Bladder Cancer AJCC v8 / Stage IVA Bladder Cancer AJCC v8 / Stage IVB Bladder Cancer AJCC v81
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCholangiocarcinoma Non-resectable / Cholangiocarcinomas / Gall Bladder Carcinoma / Gallbladder Carcinoma Non-Resectable1
2RecruitingTreatmentEndometrial Cancers / Endometrial Carcinoma / Endometrial Carcinosarcoma / Recurrent Endometrial Cancer / Recurrent Endometrial Carcinoma1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
2RecruitingTreatmentGerm Cell Tumors1
2RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentHepatocellular,Carcinoma / Intermediate Stage of Hepatocellular Carcinoma1
2RecruitingTreatmentInvasive Bladder Cancer1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentMalignancies / Rare Diseases1
2RecruitingTreatmentMalignant Neoplasm of Female Genital Organ1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentMetastatic Adult Soft Tissue Sarcoma / Recurrent Adult Soft Tissue Sarcoma1
2RecruitingTreatmentMetastatic Colorectal Cancers2
2RecruitingTreatmentMetastatic Medullary Thyroid Cancer / Metastatic Thyroid Follicular Carcinoma / Metastatic Thyroid Papillary Carcinoma1
2RecruitingTreatmentMuscle-invasive Bladder Cancer1
2RecruitingTreatmentNeuroendocrine Neoplasm of Lung / Neuroendocrine Tumors1
2RecruitingTreatmentOropharyngeal Squamous Cell Carcinoma1
2RecruitingTreatmentPeritoneal Mesotheliomas / Pleural Mesotheliomas1
2RecruitingTreatmentPlatinum Refractory Extensive-Stage Small Cell Lung Carcinoma1
2RecruitingTreatmentPlatinum-resistant Recurrent Ovarian Cancer1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
2RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v71
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentTransitional Cell Carcinoma1
2SuspendedTreatmentMesothelioma1
2Unknown StatusTreatmentMesothelioma, Malignant2
2WithdrawnTreatmentBladder Cancers1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV)1
2WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v71
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non Small Cell Lung Carcinoma NSCLC1
3Active Not RecruitingTreatmentRecurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN1
3Active Not RecruitingTreatmentSmall Cell Lung Carcinoma Extensive Disease1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedTreatmentMelanoma1
3No Longer AvailableNot AvailableAdvanced Unresectable Melanoma1
3RecruitingTreatmentBladder Cancers / Urothelial Cancer1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentMetastatic Urothelial Cancer / Unresectable Locally Advanced Urothelial Cancer1
3RecruitingTreatmentRenal Cell Adenocarcinoma1
Not AvailableActive Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Metastatic Renal Cell Cancer / Renal Cancers / Stage IV Renal Cell Cancer AJCC V71
Not AvailableActive Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
Not AvailableTerminatedNot AvailableMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:46 / Updated on May 01, 2019 11:16